ABSTRACT
Paraneoplastic syndromes have a variety of clinical manifestations most frequently resembling systemic diseases and phlebothrombosis. Also, hypercoagulative paraneoplasic syndrome may have some clinical features of myocardial infarction which makes difficult nosological diagnostics.
Subject(s)
Colonic Neoplasms/complications , Myocardial Infarction/etiology , Paraneoplastic Syndromes/diagnosis , Colonic Neoplasms/diagnosis , Diagnosis, Differential , Echocardiography , Electrocardiography , Fatal Outcome , Follow-Up Studies , Humans , Male , Middle Aged , Myocardial Infarction/diagnosisABSTRACT
The aim of the work was to study the role of atorvastatin in the correction of oxidative stress manifestations in patients with coronary heart disease and dyslipidemnia (DLP). It included 122 patients with stable forms of CHD and 20 practically healthy subjects. Plasma lipids and products of lipid peroxidation (dienic conjugates and compounds reacting with 2-thiobarbituric acid), eryhrocyte antioxidative enzymes glutathione peroxidase and superoxide dismutase were determined by standard methods; activity of the ceruloplasmin/transferrin antioxidant system) was measured by electron paramagnetic resonance. The patients underwent 24 hr ECG Holter monitoring. Atorvastatin at a dose of 20 mg/d given during 6 months exerted antioxidative and antiperoxidative effects in 90% of the patients. It normalized parameters of lipid peroxidation and antioxidant protection thereby improving the clinical course of CHD.
Subject(s)
Coronary Disease/drug therapy , Heptanoic Acids/pharmacology , Obesity/complications , Oxidative Stress/drug effects , Pyrroles/pharmacology , Adult , Aged , Antioxidants/metabolism , Antioxidants/pharmacology , Antioxidants/therapeutic use , Atorvastatin , Case-Control Studies , Coronary Disease/physiopathology , Dyslipidemias/drug therapy , Dyslipidemias/physiopathology , Electrocardiography, Ambulatory , Electron Spin Resonance Spectroscopy , Female , Heptanoic Acids/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Lipid Peroxidation/drug effects , Lipids/blood , Middle Aged , Pyrroles/therapeutic useABSTRACT
Therapeutic and prophylactic antiarrhythmic efficacy of sotalol hydrochloride (Sotahexal, "Hexal", Germany) and its effects in intracardiac hemodynamics and ECG parameters were evaluated in 95 patients with ischemic heart disease (IHD). The highest response to the drug was observed in ventricular extrasystoles, arterial flutter and fibrillation. Acute episodes of arrhythmia are managed by bolus administration of Sotahexal [correction of Hexal]. In this case greater risk of side effects exists. It is desirable to decide on the drug dose, mode of administration on the individual basis with due consideration of the risks and dangers which could be avoided in case of adequate instrumental control.
